Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu

KW-3357 Study in Patients With Early Onset Severe Preeclampsia

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04182373
Recruitment Status : Recruiting
First Posted : December 2, 2019
Last Update Posted : December 9, 2019
Sponsor:
Collaborator:
Japan Blood Products Organization
Information provided by (Responsible Party):
Kyowa Kirin Co., Ltd.

Brief Summary:
The purpose of this study is to evaluate the efficacy of intravenous KW-3357 in patients with early-onset severe preeclampsia by comparing the prolongation days of pregnancy with that of placebo.

Condition or disease Intervention/treatment Phase
Preeclampsia Drug: Antithrombin gamma Drug: physiological saline Phase 3

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 180 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double (Participant, Investigator)
Primary Purpose: Treatment
Official Title: A Phase 3, Randomized, Placebo-controlled, Double Blind Study of KW-3357 in Patients With Early Onset Severe Preeclampsia
Actual Study Start Date : November 19, 2019
Estimated Primary Completion Date : May 2022
Estimated Study Completion Date : June 2022

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Experimental: KW-3357
72 IU/kg
Drug: Antithrombin gamma
Intravenous infusion, once a day, 7 days

Placebo Comparator: placebo Drug: physiological saline
Intravenous infusion, once a day, 7 days




Primary Outcome Measures :
  1. Days of maintaining pregnancy [ Time Frame: Subjects will be observed until maternal and/or fetal indications for delivery necessitate cessation of expectant management or until approximately 34 0/7 weeks of gestation. ]

Secondary Outcome Measures :
  1. Presence or absence of achievement of 32 weeks of gestation [ Time Frame: 28 days before the end of study ]
  2. Presence or absence of achievement of 34 weeks of gestation [ Time Frame: 28 days before the end of study ]
  3. Presence or absence of achievement of 28 weeks of gestation in subjects enrolled in the period of less than 28 weeks of gestation [ Time Frame: 28 days before the end of study ]
  4. Change in AT activity [ Time Frame: From baseline to Day 8 at all time points and 3 days after termination of pregnancy ]
  5. Change in PLT concentration [ Time Frame: From baseline to Day 8 at all time points and 3 days after termination of pregnancy ]
  6. Change on D-dimer concentration [ Time Frame: From baseline to Day 8 at all time points ]
  7. Change in FDP concentration [ Time Frame: From baseline to Day 8 at all time points ]
  8. Sitting systolic blood pressure and sitting diastolic blood pressure [ Time Frame: From baseline to Day 8 at each time point, 3 days after termination of pregnancy, and 28 days after termination of pregnancy ]
  9. Proteinuria/creatinine ratio [ Time Frame: From baseline to Day 8 at each time point, 3 days after termination of pregnancy, and 28 days after termination of pregnancy ]
  10. Amount of blood lost during delivery [ Time Frame: 28 days before the end of study ]
  11. Biophysical Profile Score [ Time Frame: From baseline to Day 8 at each time point ]
    Minimum is 0, max is 10. Higher score means better condition.

  12. Fetal growth rate [ Time Frame: 28 days before the end of study ]
  13. Apgar score [ Time Frame: At 1 minute and 5 minutes after birth ]
    Minimum is 0, max is 10. Higher score means better condition.

  14. Presence or absence of neonatal asphyxia [ Time Frame: At 1 minute and 5 minutes after birth ]
  15. Birth weight [ Time Frame: 28 days before the end of study ]
  16. Neonatal growth [ Time Frame: 28 days before the end of study ]
    Fetal growth is classified into small for gestational age (SGA), appropriate for gestational age (AGA), and large for gestational age (LGA).

  17. Head and chest circumferences at birth [ Time Frame: 28 days before the end of study ]
  18. Short-term prognosis of neonates (incidence of bronchopulmonary dysplasia, intraventricular hemorrhage, periventricular leukolame, retinopathy of prematurity, sepsis, necrotizing enteritis, death, etc) [ Time Frame: 28 days after termination of pregnancy ]
  19. The number of neonates who was hospitalized in the NICU [ Time Frame: 28 days after termination of pregnancy ]
  20. The number of days in the NICU [ Time Frame: 28 days after termination of pregnancy ]
  21. The number of neonates with respiratory management at the time of admission to the NICU [ Time Frame: 28 days after termination of pregnancy ]
  22. The number of days of respiratory management at the time of admission to the NICU [ Time Frame: 28 days after termination of pregnancy ]

Other Outcome Measures:
  1. Change in TNF-alpha at the time of examination [ Time Frame: From baseline to Day 8 ]
  2. Change in interleukin (IL)-6 at the time of examination [ Time Frame: From baseline to Day 8 ]
  3. Change in IL-10 at the time of examination [ Time Frame: From baseline to Day 8 ]
  4. Change in hs-CRP at the time of examination [ Time Frame: From baseline to Day 8 ]
  5. Change in sFlt-1 at the time of examination [ Time Frame: From baseline to Day 8 ]
  6. Change in PlGF at the time of examination [ Time Frame: From baseline to Day 8 ]
  7. Change in sFlt-1/PlGF at the time of examination [ Time Frame: From baseline to Day 8 ]
  8. Pulsatility index of the umbilical artery and middle cerebral artery [ Time Frame: At the time of examination from baseline to Day 8 ]
  9. Change in findings of the umbilical artery and middle cerebral artery [ Time Frame: At the time of examination from baseline to Day 8 ]
  10. Distribution of reasons for termination of pregnancy [ Time Frame: 28 days before the end of study ]
  11. Prolongation days of pregnancy by reason of termination of pregnancy [ Time Frame: 28 days before the end of study ]
  12. Mode of delivery [ Time Frame: 28 days before the end of study ]
  13. Presence or absence of stillbirth [ Time Frame: 28 days before the end of study. Neonates will be assessed after delivery. ]
  14. Placental weight [ Time Frame: 28 days before the end of study ]
  15. Presence or absence of placental infarction [ Time Frame: 28 days before the end of study ]
  16. Umbilical arterial blood gas at termination of pregnancy [ Time Frame: 28 days before the end of study ]
  17. Presence or absence of HELLP syndromes and onset of symptoms [ Time Frame: During the course of the clinical trial. Period from the day of commencement of administration of the investigational drug to Day 28 after the delivery ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   20 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   Female
Gender Based Eligibility:   Yes
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Patients who gave written consent to participate in the clinical trial by their own free will.
  2. Patients aged 20 years or older at the time of obtaining informed consent
  3. Patients with early-onset PE* 24 weeks 0 days to 31 weeks 6 days of gestation at the time of enrollment

    *: Determine the definition of gestational age based on the "Guidelines for Obstetrics and Gynecology, Obstetrics, 2017"

  4. Patients diagnosed with severe PE*

    *: Follow the diagnostic criteria of the Japan Society for the Study of Hypertension in Pregnancy

  5. Patients with AT activity of 100% or less in the preliminary examination

Exclusion Criteria:

  1. Patients who are judged to require immediate delivery*

    *"Best Practice Guide 2015 for Care and Treatment of Hypertension in Pregnancy" Requirements for Considering Pregnancy Termination Regardless of Pregnancy Weeks in Pregnancy-induced Hypertension Syndrome Cases will be consulted for judgment.

  2. Patients with right hypochondralgia or epigastralgia
  3. Patients with HELLP syndromes
  4. Patients with pulmonary edema
  5. Patients with severe pleural effusion, severe ascites, or serous retinal detachment
  6. Patients with central nervous system disorders (eclampsia, stroke) or visual disorders (cortical blindness)
  7. Patients with severe headache or urge eclampsia
  8. Patients with abruptio placentae
  9. Suspected patients with 8 or more obstetric DIC scores
  10. Patients with a definitive diagnosis of congenital AT deficiency
  11. Patients with diseases or symptoms other than the primary disease requiring immediate delivery
  12. Patients on ongoing treatment with nonsteroidal anti-inflammatory drugs (NSAIDs, e.g., aspirin) or who require NSAIDs use during the course of the study.
  13. Patients who have received the following drugs within 72 hours before administration of the investigational product, etc., or who require administration of the following drugs during the study period (from the start of administration of the investigational product, etc., until the date of termination of pregnancy); heparin, low-molecular-weight heparin (e.g., enoxaparin or dalteparin), fondaparinux, antiplatelet drugs (e.g., clopidogrel, prasugrel, aspirin), direct thrombin inhibitors (e.g., dabigatran), or anticoagulants (e.g., AT preparations).
  14. Patients with a current or past history of serious drug allergy
  15. Patients with a history or complication of drug dependence or alcoholism
  16. Patients with hypersensitivity to AT preparations
  17. Patients who are pregnant with a fetus with a chromosomal abnormality or a fetus suspected of having a serious malformation syndrome
  18. Patients with multiple pregnancies
  19. Patients with a history or complication of antiphospholipid antibody syndrome
  20. Patients with diabetes complicated pregnancy, obvious diabetes mellitus, or insulin use
  21. Patients with uncontrollable or significant complications, including the following

    • Clinically significant cardiovascular diseases, etc. (New York Heart Association cardiac function classifications Class III or higher)
    • Serious hepatic disease
    • Serious renal disease
    • Pneumonia, interstitial lung disease or other severe respiratory disease
    • Blood disorders such as idiopathic thrombocytopenic purpura
    • Psycho-central nervous system disorders that may affect informed consent
    • Endocrine disorders such as hyperthyroidism
    • Autoimmune diseases such as systemic lupus erythematosus
  22. Patients with active malignancy or patients with a history of onset or treatment of malignancy within 5 years before pregnancy (excluding excised or surgically cured basal cell carcinoma of the skin, squamous cell carcinoma of the skin or ductal carcinoma of the breast)
  23. Patients with active infections (e.g., toxoplasma infection, genital chlamydia, genital herpes, cytomegalovirus infection)
  24. Patients with a positive history for HIV antibody. Patients with a positive history for HBs antigen and HCV antibody and with active infection presenting with hepatitis symptoms.
  25. Patients with any of the following laboratory abnormalities in preliminary examinations; Patients with AST or ALT 2 times the upper limit of the reference level of the trial site; Cr >=1.1 mg/dL
  26. Patients who have participated in a clinical trial or equivalent study of a drug or medical device within 4 months before pregnancy (within 6 months for biologics) and have received the investigational drug or used an unapproved medical device
  27. Other patients whom the principal investigator or the subinvestigator judges to be unfavorable for participation in the clinical trial

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04182373


Contacts
Layout table for location contacts
Contact: Kyowa Kirin Co., Ltd +81-3-5205-7200 clinical.info.jp@kyowakirin.com

Locations
Layout table for location information
Japan
Juntendo University Shizuoka Hospital Recruiting
Izunokuni, Japan
Sponsors and Collaborators
Kyowa Kirin Co., Ltd.
Japan Blood Products Organization
Layout table for additonal information
Responsible Party: Kyowa Kirin Co., Ltd.
ClinicalTrials.gov Identifier: NCT04182373    
Other Study ID Numbers: 3357-101
First Posted: December 2, 2019    Key Record Dates
Last Update Posted: December 9, 2019
Last Verified: December 2019
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Undecided

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Kyowa Kirin Co., Ltd.:
Preeclampsia
Antithrombin
Additional relevant MeSH terms:
Layout table for MeSH terms
Pre-Eclampsia
Hypertension, Pregnancy-Induced
Pregnancy Complications
Antithrombins
Antithrombin III
Serine Proteinase Inhibitors
Protease Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Anticoagulants